6 April 2016 - Bristol-Myers Squibb Company announced today that the European Commission has approved Opdivo (nivolumab) monotherapy for an additional indication in advanced renal cell carcinoma (RCC) after prior therapy in adults.

Opdivo is the first and only PD-1 immune checkpoint inhibitor approved in Europe to demonstrate an overall survival benefit versus a standard of care in this patient population. This approval allows for the expanded marketing of Opdivo in previously treated advanced RCC in all 28 Member States of the European Union.

For more details, go to: http://news.bms.com/press-release/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-previously-treated&t=635955562899873235